View ValuationMPS Pharmaa 将来の成長Future 基準チェック /06現在、 MPS Pharmaaの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長16.2%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • May 18MPS Pharmaa Limited to Report Q4, 2026 Results on May 28, 2026MPS Pharmaa Limited announced that they will report Q4, 2026 results on May 28, 2026お知らせ • Jan 22MPS Pharmaa Limited to Report Q3, 2026 Results on Feb 02, 2026MPS Pharmaa Limited announced that they will report Q3, 2026 results on Feb 02, 2026お知らせ • Nov 04MPS Pharmaa Limited to Report Q2, 2026 Results on Nov 14, 2025MPS Pharmaa Limited announced that they will report Q2, 2026 results on Nov 14, 2025お知らせ • Sep 03MPS Pharmaa Limited, Annual General Meeting, Sep 29, 2025MPS Pharmaa Limited, Annual General Meeting, Sep 29, 2025, at 09:30 Indian Standard Time. Location: 138, roz-ka-meo industrial area, sohna, distt, mewat- 122103, haryana, Indiaお知らせ • Aug 02MPS Pharmaa Limited to Report Q1, 2026 Results on Aug 12, 2025MPS Pharmaa Limited announced that they will report Q1, 2026 results on Aug 12, 2025お知らせ • May 19MPS Pharmaa Limited to Report Q4, 2025 Results on May 28, 2025MPS Pharmaa Limited announced that they will report Q4, 2025 results on May 28, 2025お知らせ • Oct 31MPS Pharmaa Limited to Report Q2, 2025 Results on Nov 14, 2024MPS Pharmaa Limited announced that they will report Q2, 2025 results on Nov 14, 2024お知らせ • Sep 03MPS Pharmaa Limited, Annual General Meeting, Sep 28, 2024MPS Pharmaa Limited, Annual General Meeting, Sep 28, 2024, at 09:30 Indian Standard Time. Location: 138, roz-ka-meo industrial area, sohna, distt, mewat- 122103, haryana, Indiaお知らせ • Jul 30MPS Pharmaa Limited to Report Q1, 2025 Results on Aug 13, 2024MPS Pharmaa Limited announced that they will report Q1, 2025 results on Aug 13, 2024お知らせ • May 16MPS Pharmaa Limited to Report Q4, 2024 Results on May 30, 2024MPS Pharmaa Limited announced that they will report Q4, 2024 results on May 30, 2024お知らせ • Oct 31MPS Pharmaa Limited to Report Q2, 2023 Results on Nov 09, 2023MPS Pharmaa Limited announced that they will report Q2, 2023 results on Nov 09, 2023お知らせ • Aug 30MPS Pharmaa Limited, Annual General Meeting, Sep 29, 2023MPS Pharmaa Limited, Annual General Meeting, Sep 29, 2023, at 09:30 Indian Standard Time.お知らせ • Aug 03MPS Pharmaa Limited to Report Q1, 2024 Results on Aug 12, 2023MPS Pharmaa Limited announced that they will report Q1, 2024 results at 3:30 PM, Indian Standard Time on Aug 12, 2023お知らせ • Jul 06MPS Pharmaa Limited Announces Resignation of Manoj Kumar Jain from the Position of the Independent Director of the Company with Immediate EffectMPS Pharmaa Limited announced that the company has received on 05th July, 2023, a resignation letter dated 04th July, 2023 from Mr. Manoj Kumar Jain, Independent Director of the Company wherein he has tendered his resignation from the position of the Independent Director of the Company with immediate effect. Resignation due to personal reasons commitments and business commitments. Mr. Manoj Kumar Jain has been associated with the company since 26-12-2013.Board Change • Jun 26Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • May 17MPS Pharmaa Limited to Report Q4, 2023 Results on May 29, 2023MPS Pharmaa Limited announced that they will report Q4, 2023 results on May 29, 2023Board Change • Mar 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Feb 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Feb 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jan 24MPS Pharmaa Limited to Report Q3, 2023 Results on Feb 03, 2023MPS Pharmaa Limited announced that they will report Q3, 2023 results on Feb 03, 2023Board Change • Jan 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Jan 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Nov 21Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Nov 03Advik Laboratories Limited to Report Q2, 2023 Results on Nov 12, 2022Advik Laboratories Limited announced that they will report Q2, 2023 results on Nov 12, 2022Board Change • Oct 31Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Oct 10Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Sep 19Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Sep 02Advik Laboratories Limited, Annual General Meeting, Sep 29, 2022Advik Laboratories Limited, Annual General Meeting, Sep 29, 2022, at 09:30 Indian Standard Time. Location: 138, Roz- Ka - Meo Industrial Area, Sohna, Distt. Mewat-122 103, Haryana Sohna IndiaBoard Change • Sep 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 16First quarter 2023 earnings released: ₹0.11 loss per share (vs ₹0.15 loss in 1Q 2022)First quarter 2023 results: ₹0.11 loss per share (up from ₹0.15 loss in 1Q 2022). Net loss: ₹2.03m (loss narrowed 27% from 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 24% per year, which means it is well ahead of earnings.お知らせ • Jul 31Advik Laboratories Limited to Report Q1, 2023 Results on Aug 12, 2022Advik Laboratories Limited announced that they will report Q1, 2023 results on Aug 12, 2022お知らせ • Apr 16Advik Laboratories Limited announced that it expects to receive INR 62.5 million in funding from Neelabh Spinning Mills Pvt. Ltd., Omkam Securities Private Limited, Dhiru Builders and Promoters Private Limited and other investorsAdvik Laboratories Limited announced a private placement of up to 25,000,000 pre-paid warrants at a price of INR 2.5 per warrant for gross proceeds of up to INR 62,500,000 on April 15, 2022. The transaction will include participation from promoters Aditya Aggarwal, Seema Aggarwal, and Omkam Securities Private Limited, and non-promoters Neelabh Spinning Mills Pvt. Ltd., and returning investor Dhiru Builders and Promoters Private Limited. The total issue price of warrants is INR 10, of which the company will receive 25% as upfront payment at the time of allotment of warrants and the remaining 75% will be paid upon exercise of warrants. Each warrant is exercisable to acquire 1 common share of the company, at an exercise price of INR 7.5 per share for a period of 18 months from the date of closing. The company will issue securities on preferential basis. The transaction has been approved by the board of directors of the company, and is subject to approval from company's shareholders at its extraordinary general meeting scheduled to be held on May 18, 2022, and approval from applicable regulatory authorities.Reported Earnings • Jul 06Full year 2021 earnings released: ₹2.31 loss per share (vs ₹0.61 loss in FY 2020)Full year 2021 results: Net loss: ₹44.2m (loss widened 279% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has only fallen by 35% per year, which means it has not declined as severely as earnings. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、MPS Pharmaa は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測BSE:531686 - アナリストの将来予測と過去の財務データ ( )INR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20260-10-6-6N/A12/31/20250-9N/AN/AN/A9/30/20250-9-5-6N/A6/30/20250-9N/AN/AN/A3/31/20250-9-6-6N/A12/31/20241-9N/AN/AN/A9/30/20240-9-7-6N/A6/30/20241-9N/AN/AN/A3/31/20241-8-7-6N/A12/31/20231-9N/AN/AN/A9/30/20231-9-7-7N/A6/30/20231-10N/AN/AN/A3/31/20230-11-10-9N/A12/31/20220-3N/AN/AN/A9/30/20220-323N/A6/30/20220-1N/AN/AN/A3/31/20220-1-44-43N/A12/31/20213-7N/AN/AN/A9/30/20213-42-59-59N/A6/30/20212-44N/AN/AN/A3/31/2021N/A-44-9-9N/A12/31/20200-46N/AN/AN/A9/30/20200-11-4-4N/A6/30/20200-12N/AN/AN/A3/31/20200-12-5-5N/A12/31/20190-11N/AN/AN/A9/30/20190-12N/A1N/A6/30/20199-12N/AN/AN/A3/31/20198-12N/A6N/A12/31/20189-11N/AN/AN/A9/30/201821-11N/AN/AN/A6/30/201828-10N/AN/AN/A3/31/201841-9N/A-3N/A12/31/201746-34N/AN/AN/A9/30/201744-34N/AN/AN/A6/30/201737-35N/AN/AN/A3/31/201729-74N/A4N/A12/31/201632-44N/AN/AN/A9/30/20163-46N/AN/AN/A6/30/2016-3-47N/AN/AN/A3/31/201614-12N/A13N/A12/31/201519-21N/AN/AN/A9/30/201567-17N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 531686の予測収益成長が 貯蓄率 ( 6.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 531686の収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 531686の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 531686の収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 531686の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 531686の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/13 08:50終値2026/07/06 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋MPS Pharmaa Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 18MPS Pharmaa Limited to Report Q4, 2026 Results on May 28, 2026MPS Pharmaa Limited announced that they will report Q4, 2026 results on May 28, 2026
お知らせ • Jan 22MPS Pharmaa Limited to Report Q3, 2026 Results on Feb 02, 2026MPS Pharmaa Limited announced that they will report Q3, 2026 results on Feb 02, 2026
お知らせ • Nov 04MPS Pharmaa Limited to Report Q2, 2026 Results on Nov 14, 2025MPS Pharmaa Limited announced that they will report Q2, 2026 results on Nov 14, 2025
お知らせ • Sep 03MPS Pharmaa Limited, Annual General Meeting, Sep 29, 2025MPS Pharmaa Limited, Annual General Meeting, Sep 29, 2025, at 09:30 Indian Standard Time. Location: 138, roz-ka-meo industrial area, sohna, distt, mewat- 122103, haryana, India
お知らせ • Aug 02MPS Pharmaa Limited to Report Q1, 2026 Results on Aug 12, 2025MPS Pharmaa Limited announced that they will report Q1, 2026 results on Aug 12, 2025
お知らせ • May 19MPS Pharmaa Limited to Report Q4, 2025 Results on May 28, 2025MPS Pharmaa Limited announced that they will report Q4, 2025 results on May 28, 2025
お知らせ • Oct 31MPS Pharmaa Limited to Report Q2, 2025 Results on Nov 14, 2024MPS Pharmaa Limited announced that they will report Q2, 2025 results on Nov 14, 2024
お知らせ • Sep 03MPS Pharmaa Limited, Annual General Meeting, Sep 28, 2024MPS Pharmaa Limited, Annual General Meeting, Sep 28, 2024, at 09:30 Indian Standard Time. Location: 138, roz-ka-meo industrial area, sohna, distt, mewat- 122103, haryana, India
お知らせ • Jul 30MPS Pharmaa Limited to Report Q1, 2025 Results on Aug 13, 2024MPS Pharmaa Limited announced that they will report Q1, 2025 results on Aug 13, 2024
お知らせ • May 16MPS Pharmaa Limited to Report Q4, 2024 Results on May 30, 2024MPS Pharmaa Limited announced that they will report Q4, 2024 results on May 30, 2024
お知らせ • Oct 31MPS Pharmaa Limited to Report Q2, 2023 Results on Nov 09, 2023MPS Pharmaa Limited announced that they will report Q2, 2023 results on Nov 09, 2023
お知らせ • Aug 30MPS Pharmaa Limited, Annual General Meeting, Sep 29, 2023MPS Pharmaa Limited, Annual General Meeting, Sep 29, 2023, at 09:30 Indian Standard Time.
お知らせ • Aug 03MPS Pharmaa Limited to Report Q1, 2024 Results on Aug 12, 2023MPS Pharmaa Limited announced that they will report Q1, 2024 results at 3:30 PM, Indian Standard Time on Aug 12, 2023
お知らせ • Jul 06MPS Pharmaa Limited Announces Resignation of Manoj Kumar Jain from the Position of the Independent Director of the Company with Immediate EffectMPS Pharmaa Limited announced that the company has received on 05th July, 2023, a resignation letter dated 04th July, 2023 from Mr. Manoj Kumar Jain, Independent Director of the Company wherein he has tendered his resignation from the position of the Independent Director of the Company with immediate effect. Resignation due to personal reasons commitments and business commitments. Mr. Manoj Kumar Jain has been associated with the company since 26-12-2013.
Board Change • Jun 26Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • May 17MPS Pharmaa Limited to Report Q4, 2023 Results on May 29, 2023MPS Pharmaa Limited announced that they will report Q4, 2023 results on May 29, 2023
Board Change • Mar 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Feb 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Feb 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jan 24MPS Pharmaa Limited to Report Q3, 2023 Results on Feb 03, 2023MPS Pharmaa Limited announced that they will report Q3, 2023 results on Feb 03, 2023
Board Change • Jan 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Jan 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Nov 21Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Nov 03Advik Laboratories Limited to Report Q2, 2023 Results on Nov 12, 2022Advik Laboratories Limited announced that they will report Q2, 2023 results on Nov 12, 2022
Board Change • Oct 31Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Oct 10Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Sep 19Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Sep 02Advik Laboratories Limited, Annual General Meeting, Sep 29, 2022Advik Laboratories Limited, Annual General Meeting, Sep 29, 2022, at 09:30 Indian Standard Time. Location: 138, Roz- Ka - Meo Industrial Area, Sohna, Distt. Mewat-122 103, Haryana Sohna India
Board Change • Sep 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 16First quarter 2023 earnings released: ₹0.11 loss per share (vs ₹0.15 loss in 1Q 2022)First quarter 2023 results: ₹0.11 loss per share (up from ₹0.15 loss in 1Q 2022). Net loss: ₹2.03m (loss narrowed 27% from 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 24% per year, which means it is well ahead of earnings.
お知らせ • Jul 31Advik Laboratories Limited to Report Q1, 2023 Results on Aug 12, 2022Advik Laboratories Limited announced that they will report Q1, 2023 results on Aug 12, 2022
お知らせ • Apr 16Advik Laboratories Limited announced that it expects to receive INR 62.5 million in funding from Neelabh Spinning Mills Pvt. Ltd., Omkam Securities Private Limited, Dhiru Builders and Promoters Private Limited and other investorsAdvik Laboratories Limited announced a private placement of up to 25,000,000 pre-paid warrants at a price of INR 2.5 per warrant for gross proceeds of up to INR 62,500,000 on April 15, 2022. The transaction will include participation from promoters Aditya Aggarwal, Seema Aggarwal, and Omkam Securities Private Limited, and non-promoters Neelabh Spinning Mills Pvt. Ltd., and returning investor Dhiru Builders and Promoters Private Limited. The total issue price of warrants is INR 10, of which the company will receive 25% as upfront payment at the time of allotment of warrants and the remaining 75% will be paid upon exercise of warrants. Each warrant is exercisable to acquire 1 common share of the company, at an exercise price of INR 7.5 per share for a period of 18 months from the date of closing. The company will issue securities on preferential basis. The transaction has been approved by the board of directors of the company, and is subject to approval from company's shareholders at its extraordinary general meeting scheduled to be held on May 18, 2022, and approval from applicable regulatory authorities.
Reported Earnings • Jul 06Full year 2021 earnings released: ₹2.31 loss per share (vs ₹0.61 loss in FY 2020)Full year 2021 results: Net loss: ₹44.2m (loss widened 279% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has only fallen by 35% per year, which means it has not declined as severely as earnings.